Dr Sapna Patel speaks to ecancer about an ongoing phase 1a/b trial evaluating IMA203, a PRAME-directed T-cell receptor therapy in patients with metastatic uveal melanoma.

The results of this trial showed a 67% confirmed objective response rate with tumour shrinkage observed in all treated patients.

Dr Patel highlights that IMA203 induced durable responses with a median duration of response of 11 months and a median overall survival of 16.2 months. The treatment was generally well tolerated with manageable cytokine release syndrome and minimal neurotoxicity.

Dr Patel concludes by saying that these findings highlight IMA203 as a promising targeted cellular therapy for a disease with limited treatment options and poor prognosis.